

AMICUS THERAPEUTICS INC

Form 4

June 07, 2007

FORM 4**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

Check this box
if no longer
subject to
Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB
Number: 3235-0287
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *
Weinhoff Gregory M

(Last) (First) (Middle)

C/O CHL MEDICAL
PARTNERS, 1055 WASHINGTON
BLVD.

(Street)

STAMFORD, CT 06901

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading
Symbol
AMICUS THERAPEUTICS INC
[FOLD]

3. Date of Earliest Transaction
(Month/Day/Year)
06/05/2007

4. If Amendment, Date Original
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

☒ Director ☐ 10% Owner
☐ Officer (give title below) ☐ Other (specify below)

6. Individual or Joint/Group Filing(Check
Applicable Line)
☒ Form filed by One Reporting Person
☐ Form filed by More than One Reporting
Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/05/2007		C	1,975,223	A 11 2,108,555	I	By Partnership (4)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of
information contained in this form are not
required to respond unless the form
displays a currently valid OMB control
number.**

SEC 1474
(9-02)

Edgar Filing: AMICUS THERAPEUTICS INC - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)
				Code	V (A) (D)	Date Exercisable Expiration Date	Title Amount Number Shares
Series A Convertible Preferred Stock	<u>(1)</u>	06/05/2007		C	83,278	04/15/2002 <u>(1)</u>	Common Stock 83,278
Series A Convertible Preferred Stock	<u>(1)</u>	06/05/2007		C	5,611	04/15/2002 <u>(1)</u>	Common Stock 5,611
Series B Convertible Preferred Stock	<u>(1)</u>	06/05/2007		C	734,803	05/04/2004 <u>(1)</u>	Common Stock 734,803
Series B Convertible Preferred Stock	<u>(1)</u>	06/05/2007		C	49,509	05/04/2004 <u>(1)</u>	Common Stock 49,509
Series B Convertible Preferred Stock	<u>(1)</u>	06/05/2007		C	11,182	04/18/2006 <u>(1)</u>	Common Stock 11,182
Series B Convertible Preferred Stock	<u>(1)</u>	06/05/2007		C	753	04/18/2006 <u>(1)</u>	Common Stock 753
Series C Convertible Preferred	<u>(1)</u>	06/05/2007		C	247,850	08/16/2005 <u>(1)</u>	Common Stock 247,850

Edgar Filing: AMICUS THERAPEUTICS INC - Form 4

Stock

Series C
Convertible
Preferred
Stock

(1)

06/05/2007

C

16,669

08/16/2005

(1)

Common
Stock

16,699

Series C
Convertible
Preferred
Stock

(1)

06/05/2007

C

247,850

04/17/2006

(1)

Common
Stock

247,850

Series C
Convertible
Preferred
Stock

(1)

06/05/2007

C

16,669

04/17/2006

(1)

Common
Stock

16,699

Series D
Convertible
Preferred
Stock

(1)

06/05/2007

C

96,233

09/13/2006

(1)

Common
Stock

96,233

Series D
Convertible
Preferred
Stock

(1)

06/05/2007

C

6,484

09/13/2006

(1)

Common
Stock

6,484

Series D
Convertible
Preferred
Stock

(1)

06/05/2007

C

96,223

03/09/2007

(1)

Common
Stock

96,233

Series D
Convertible
Preferred
Stock

(1)

06/05/2007

C

6,484

03/09/2007

(1)

Common
Stock

6,484

Series A
Convertible
Preferred
Stock

(1)

06/05/2007

C

333,111

07/15/2002

(1)

Common
Stock

333,111

Series A
Convertible
Preferred
Stock

(1)

06/05/2007

C

22,444 07/15/2002

(1)

Common
Stock

22,444

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Weinhoff Gregory M C/O CHL MEDICAL PARTNERS 1055 WASHINGTON BLVD. STAMFORD, CT 06901		X		

Signatures

/s/ Gregory M.
Weinhoff

06/06/2007

**Signature of Reporting
Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) Each of the Series A Convertible Preferred Stock, the Series B Convertible Preferred Stock, the Series C Convertible Preferred Stock and the Series D Convertible Preferred Stock automatically converted into Amicus Therapeutics, Inc. common stock on a one-for-one basis upon the closing of Amicus Therapeutics, Inc.'s initial public offering on June 5, 2007

- (2) The reporting person is a partner of Collinson, Howe & Lennox II, LLC, which is the general partner of CHL Medical Partners II, L.P. Voting and investment power over these shares is exercised by Collinson, Howe & Lennox II, LLC in its role as general partner and investment advisor of CHL Medical Partners II, L.P. The reporting person disclaims beneficial ownership of these shares except to the extent of his proportionate pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the shares for purposes of section 16 or for any other purpose.

- (3) The reporting person is a partner of Collinson, Howe & Lennox II, LLC, which is the general partner of CHL Medical Partners II Side Fund, L.P. Voting and investment power over these shares is exercised by Collinson, Howe & Lennox II, LLC in its role as general partner and investment advisor of CHL Medical Partners II Side Fund, L.P. The reporting person disclaims beneficial ownership of these shares except to the extent of his proportionate pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the shares for purposes of section 16 or for any other purpose.

- (4) Consists of 1,975,456 shares held by CHL Medical Partner II, L.P. and 133,099 shares held by CHL Medical Partners II Side Fund, L.P. The reporting person is a partner of Collinson, Howe & Lennox II, LLC, which is the general partner of CHL Medical Partners II, L.P. and CHL Medical Partners II Side Fund, L.P. Voting and investment power over these shares is exercised by Collinson, Howe & Lennox II, LLC in its role as general partner and investment advisor of CHL Medical Partners II, L.P. and CHL Medical Partners II Side Fund, L.P. The reporting person disclaims beneficial ownership of these shares except to the extent of his proportionate pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the shares for purposes of section 16 or for any other purpose.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.